The prediction value of platelet-derived growth factor for major adverse cardiovascular events in patients with acute non-ST-segment elevation myocardial infarction

Abstract

Background The value of plasma Platelet-Derived Growth Factor (PDGF) as a biomarker in predicting major adverse cardiovascular events (MACEs) in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) remains unclear. Methods A total of 242 patients with NSTEMI were enrolled in this observational cohort study. The correlation between PDGF and MACEs was evaluated during a five-year follow-up. Kaplan–Meier survival analysis with Cox proportional-hazards regression was used to identify predictive values of PDGF. Results The mean follow-up of NSTEMI patients was 1334 days. It was found that as the PDGF level increased, a significant uptrend in the incidence of MACEs and all-cause death, including the MACEs of 30 days, 180 days, 1 year, 5 years and the death of 1 year and 5 years (All Log-rank p < .05). Subgroup analysis further showed that PDGF had better predictive value for patients with age >65 years, GRACE score ≥140 and platelet count (PLT) >200 × 10 9 /L. Conclusion PDGF levels can predict short-term and long-term MACEs in NSTEMI patients after discharge, especially for patients with older age, higher GRACE score and baseline PLT > 200 × 10 9 /L. Key messages PDGF is a risk factor for short- and long-term MACEs in patients with STEMI. PDGF has a better prognostic value in patients with older age and PLT > 200 × 10 9 /L. Baseline plasma PDGF levels were positively correlated with GRACE score.

Role of Systolic Blood Pressure to Left Ventricular End-Diastolic Pressure Ratio in Prediction of Major Adverse Cardiovascular Events in Patients with ST-segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention

“…This is also consistent with Sato et al [10] who investigated how the CADILLAC and GRACE risk ratings affected shortand long-term clinical outcomes in patients with acute myocardial infarction and found that 262 patients (32.4%) suffered from MACEs. However, our study is in contrast with Zhang et al [11] who studied if central arterial pressure predicts in-hospital MACEs after acute STEMI and revealed that MACEs occurred in 22.6% of patients. Also, Kumar et al [12] who studied the burden of short-term MACEs and its determinants after emergency PCI where MACEs were observed in 210 (19.1%) patients.…”

“…Regarding angiographic data, Zhang et al [11] showed that low central systolic blood pressure group had the highest incidence of in-hospital complications. Similar to our result, Tesak et al [20] showed statistically significant higher LVEDP in non-survivors group (median= 30 mmHg, range 22-39 mmHg) when compared to survivors group (24 mmHg, range 12-38 mmHg) with p-value= 0.001 & with LVEDP was independent predictor for 30-day mortality [AUC 0.715, 95% CI (0.626; 0.803), p-value <0.001, cut-off value ≥20.5 mmHg].…”

The Genetic Risk Score with Variants at PDGFs and PDGFRB for the Risk of Major Cardiovascular Adverse Events in Patients with Coronary Artery Disease

“…In this study, we observed a weak correlation between MPV, PDW, eGFR, and wGRS as well as a positive correlation between the GRACE score and wGRS, particularly among patients with NSTEMI. Consistent with our study ndings, an observational cohort study of 242 NSTEMI patients followed up for a period of 5 years, observed a positive correlation between serum level of PDGF, and MPV and GRACE score [47].Coupled with the previously mentioned observations, this intimates a potential association among PDGF-related genetic effect, platelet attributes, and the severity of acute myocardial infarction gauged by the GRACE score. More comprehensive research is necessitated to delve deeper into the putative mechanisms and clinical implications of this connection.…”